|
|
|
You can get e-magazine links on WhatsApp. Click here
|
|
|
|
|
|
TopGum completes US acquisition of PL Developments
|
|
Wednesday, 13 May, 2026, 08 : 00 AM [IST]
|
|
Ramat Gan, Israel & New York, USA
|
TopGum Industries Ltd., a global leader in gummy-format dietary supplements, and P&L Developments LLC, a leading US OTC pharmaceuticals company developing and manufacturing healthcare products, announced the completion of its acquisition of PLD's US gummy manufacturing operations. The transaction, first announced via a binding letter of intent on January 20, 2026, deepens its presence in United States, its largest target market, and positions it as a pioneer in the emerging pharmaceutical gummies market. Both companies agreed to launch a strategic commercial partnership under which it will commercialise and distribute manufactured products to leading US retailers under store-brand labels.
The completion of the transaction reinforces its position as a leading innovative company in its field and marks a significant milestone in its strategy to become a leading global player in healthcare products built on advanced, enjoyable delivery systems.
The acquisition gives it a US-based manufacturing platform purpose-built to FDA pharmaceutical standards, capable of producing both pharmaceutical gummies and dietary supplements. This state-of-the-art facility is among a select few globally to have reached operational manufacturing capability for pharmaceutical gummies.
Eyal Shohat, chief executive officer, TopGum, said, "This is a strategic transaction that gives TopGum a unique foothold in the emerging pharmaceutical gummy market and reinforces its positioning as an innovative, leading company in its field. The transaction positions TopGum as a unique player with an advanced global manufacturing platform, built to serve the largest dietary supplement brands in US with local manufacturing. Partnering with PLD, one of the leading generic pharmaceutical companies in US, gives us access to leading US retail chains and accelerates our growth in this market. The fact that a significant portion of the consideration is contingent and share-based reflects PLD’s confidence in TopGum's strategy, capabilities and long-term growth trajectory. The pharmaceutical gummy category is in its earliest innings, and we believe it will follow the same arc the dietary supplement market followed over the past 15 years, when the gummy format became the dominant one. We view the completion of the transaction as a significant milestone in TopGum's growth trajectory, and we are at the beginning of a new chapter in the Company's accelerated expansion as we continue our journey to become a leading player in healthcare products built on enjoyable, advanced delivery systems."
Evan Singer, president, P&L Development, said, "At PLD, we see gummies as an emerging platform for delivering healthcare across vitamins, minerals and supplements (VMS) and pharmaceutical products, which customers and consumers are increasingly asking for. This transaction gives us the ability to serve that demand at an even more aggressive speed and scale, by partnering with a world-class gummy manufacturing & development company. The deal structure itself is creative and delivers on two priorities at once: putting a purpose-built, FDA-compliant gummy manufacturing platform into the hands of a global category leader who will scale it, while securing PLD privileged access to TopGum's portfolio and development pipeline for our US customers. We expect to be bringing TopGum products to our retail partners in the coming months."
|
|
|
|
|
|
|
|
|
|